CagriSema
Cagrilintide + Semaglutide
CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.
作用机制
Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.
研究协议
仅供研究使用,非医疗建议。
Research protocols use the combination in a single weekly injection. Phase 3 doses range from cagrilintide 2.4mg + semaglutide 2.4mg weekly.
研究笔记
Clinical Research Status
CagriSema is in Phase 3 trials (REDEFINE program) for obesity and type 2 diabetes, with regulatory submissions anticipated based on trial readouts. Phase 2 data demonstrated approximately 15.6% body weight loss at 32 weeks, numerically superior to semaglutide 2.4mg alone. The REDEFINE 1 Phase 3 trial reported up to 22.7% weight loss at 68 weeks, positioning it competitively against tirzepatide.
Key Published Findings
The dual amylin/GLP-1 approach produces additive weight loss beyond either mechanism alone, supporting the hypothesis that multi-receptor targeting enhances metabolic outcomes. Glycemic improvements were also observed, with potential for combined diabetes and obesity indications. The mechanistic rationale rests on amylin's distinct CNS satiety signaling through the area postrema complementing GLP-1's hypothalamic and gut-mediated effects.
Safety Profile
The adverse event profile combines elements of both components, with gastrointestinal effects (nausea, vomiting, diarrhea) being most common during dose escalation. Tolerability appears manageable with appropriate titration schedules, though direct comparisons to monotherapy discontinuation rates are still being evaluated. Injection site reactions are consistent with other subcutaneous peptide therapies.
Comparison to Related Compounds
CagriSema competes directly with tirzepatide (Mounjaro/Zepbound), which uses a single molecule targeting GIP and GLP-1 receptors simultaneously. The two-molecule approach allows independent dose optimization of each component but requires a single co-formulated injection. Weight loss magnitude appears comparable to tirzepatide's 20-25% in similar trial durations, though head-to-head data is needed for definitive comparison.
Community Observations
The obesity research community views CagriSema as Novo Nordisk's answer to tirzepatide's superior weight loss over semaglutide monotherapy. Clinicians note that the combination format may offer flexibility for patients who plateau on GLP-1 monotherapy. The amylin component is reported to address residual hunger that some patients experience even at maximum GLP-1 doses.
半衰期
~7 days (combination)
复溶
Pre-mixed formulation
存储
冻干
Refrigerate 2-8C.
复溶后
Refrigerate 2-8C. Use within 42 days.
美国法律状态
又称作
常见问题
什么是 CagriSema?
CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.
CagriSema 如何起作用?
Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.
CagriSema 在美国的监管状态是什么?
Research chemical (not FDA-approved)
CagriSema 的半衰期是多少?
~7 days (combination)
CagriSema 还有哪些名称?
Cagrilintide + Semaglutide
Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。
阅读完整免责声明